What Eigen does

Eigen Health is a privately held medical technology company founded in 1975 and headquartered in California, USA. The company develops MRI-ultrasound fusion imaging devices used in prostate cancer biopsy and focal therapy. Its products are sold to hospitals, urology departments, cancer centers, and diagnostic imaging facilities globally, with operational reach across more than 36 countries. The company is led by founder Mr. Kazi's vision, and current President Mahtab Damda, and maintains ISO 13485 certification for medical device design, development, and manufacturing.

The core product is the Artemis platform, a 3D semi-robotic prostate fusion biopsy system that pairs a mechanical arm fitted with electronic encoders to scan, digitize, and track the prostate in real-time, enabling prospective needle navigation that adjusts for organ motion during the procedure. The platform supports both transrectal and transperineal biopsy approaches and performs rigid and elastic registration of MRI, PET-CT, and PSMA PET-MRI imaging to live ultrasound. The portfolio is organized as a platform-plus-modules architecture: Artemis (core), Artemis TPO (transperineal-optimized module with integrated ultrasound), NGA (the needle guidance mechanical arm component), ProFuse CAD (radiology visualization and computer-assisted detection software), and Cryo (MRI/US fusion-guided cryoablation therapy). Multiple patents underpin the MRI-ultrasound fusion and robotic-assisted biopsy technology. Over 3,000,000 patients have been supported by the platform worldwide.

Eigen generates revenue through a multi-stream medical device model: capital hardware sales of the Artemis and TPO systems, software licensing of ProFuse CAD, recurring sales of needle guides and consumables, and professional services for training, support, and clinical integration. Pricing is not publicly disclosed and follows a quote-based enterprise model typical of capital medical equipment. Go-to-market is enterprise field sales combined with a global distributor network covering 36+ countries and direct engagement via demo requests and support inquiries on the company website. Eigen participates in industry medical conferences and trade shows for top-of-funnel awareness. Customer acquisition is consultative and dependent on clinical validation, hospital procurement cycles, and integration into urology and radiology workflows.

Name

Eigen

Website

https://eigen.com

Company type

Private

Founded year

1975

Operating status

Operating

Headcount range

251–500 employees

Short description

Eigen Health, founded in 1975 in California, develops MRI-ultrasound fusion medical imaging systems, including the Artemis semi-robotic prostate biopsy platform, ProFuse CAD software, and cryoablation therapy, serving hospitals and urology centers in 36+ countries.

Ownership category

akta.pro rank

Product category

Medical Imaging Equipment

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)

akta.pro secondary industries

Surgical Navigation, Robotics & Patient-Matched Instrumentation (Ortho/Spine) (HLAHAEAL), Imaging Interoperability & Standards Enablement (DICOM/HL7/FHIR/IHE) (HLACALAJ)

Keywords

• Medical imaging devices
• Prostate biopsy systems
• MRI-ultrasound fusion
• Focal therapy equipment
• Robotic biopsy platforms

Headquarters

HQ city

Grass Valley

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Others

Revenue model

1. Medical Device Hardware Sales: Sale of the Artemis semi-robotic biopsy platform and TPO systems - capital medical equipment sold to hospitals and healthcare institutions
2. Software Licensing: ProFuse CAD radiology software licensing for MRI analysis and fusion workflow preparation
3. Accessory and Consumable Sales: Sale of needle guides and related accessories for the Artemis platform
4. Professional Services: Training, support, and integration services for clinical practice implementation

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Eigen develops and sells the Artemis semi-robotic prostate fusion biopsy system with real-time organ tracking and prospective needle navigation, integrating MRI, PET-CT, and PSMA PET-MRI data with real-time ultrasound imaging. The company also offers the TPO transperineal module, ProFuse CAD radiology software for MRI analysis, and Cryo cryoablation therapy solutions for prostate cancer diagnosis and treatment.

Product overview

Eigen Health offers a platform-plus-modules architecture centered on the Artemis semi-robotic prostate fusion biopsy system. The core Artemis platform provides 3D semi-robotic biopsy with real-time organ tracking and prospective needle navigation, supporting both transrectal and transperineal approaches. The portfolio includes the Artemis TPO module (transperineal-only variant with integrated ultrasound), the NGA needle guidance component (electronic encoder-based mechanical arm), ProFuse CAD (computer-assisted detection software for mpMRI analysis and fusion data preparation), and Cryo (cryoablation therapy combining MRI/US fusion guidance). All products integrate MRI, PET-CT, and PSMA PET-MRI data with real-time ultrasound imaging for precision prostate cancer diagnosis and treatment.

Differentiator

Problem solved

Functional benefit

Brands

• Artemis: 3D Semi-Robotic Prostate Fusion biopsy system with real-time organ tracking and prospective needle navigation. Supports both transrectal and transperineal modules with rigid and elastic registration of MRI, PET-CT and PSMA PET-MRI to real-time ultrasound images.
• TPO
• ProFuse CAD
• Cryo

Products and services

• Artemis 3D semi-robotic prostate fusion biopsy system featuring genuine real-time organ tracking and prospective needle navigation. Supports both transrectal and transperineal modules with rigid and elastic registration of MRI, PET-CT, and PSMA PET-MRI to real-time ultrasound images. Designed for hospitals, urology departments, and cancer centers performing prostate biopsies.
• Artemis TPO Transperineal approach module with integrated high-quality ultrasound option. Enables high-precision fusion and elimination of prostate deformation through rigid and elastic registration of MRI, PET-CT, and PSMA PET-MRI to real-time ultrasound images. Targeted at hospitals and urology centers performing transperineal biopsy procedures.
• ProFuse CAD Advanced visualization and computer-assisted detection software tool for real-time analysis of mpMRI of the prostate, reporting of findings, and preparation of MRI data for fusion on the Artemis biopsy system. Designed for radiologists and urology departments performing prostate MRI analysis.
• Cryo MRI/US fusion-guided prostate biopsy combined with cryoablation offering a precise, minimally invasive, and often outpatient approach to treating prostate cancer by using MRI data to guide freezing technology. Targeted at hospitals and cancer centers performing prostate cancer focal therapy.

Quantifiable outcome

• Over 3,000,000 patients supported worldwide through Eigen's technology

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Distributor PartnerscoreChannel Partner/ Reseller/ DistributorEigen operates through long-term partnerships with distributors in 36+ countries to ensure technology integrates seamlessly into clinical practice, education, and research worldwide. Distributors provide local sales, support, and training capabilities.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• MIM Software: MIM Software offers prostate MRI fusion and contouring software used in fusion biopsy workflows. It is comparable to Eigen's ProFuse CAD as a software-only fusion preparation tool integrated with downstream biopsy platforms.
• KOELIS: KOELIS is a direct competitor offering MRI-TRUS fusion prostate biopsy systems (e.g., Trinity, Prime) with elastic registration and 3D prostate mapping — highly comparable to Eigen's Artemis platform in clinical indication, workflow, and customer base (urology departments).
• Biobot Surgical: Biobot Surgical develops the iSR'obot Mona Lisa, a robotic-assisted transperineal prostate biopsy platform. It competes head-to-head with Eigen's Artemis TPO in the transperineal fusion biopsy segment.

Broad incumbents

• GE HealthCare: GE HealthCare provides prostate MR fusion and ultrasound solutions that intersect with Eigen's Artemis/ProFuse CAD workflow. It is a broad incumbent rather than a focused niche competitor in prostate biopsy robotics.
• Medtronic: Medtronic has expanded into urology robotics (Hugo) and broader surgical platforms, making it a tangential competitor for hospital capital budgets and robotic-surgery mindshare that Eigen's Artemis platform also targets.
• Intuitive Surgical: Intuitive Surgical (da Vinci) dominates surgical robotics in urology. While not a direct fusion-biopsy competitor, it defines the robotic-surgery standard that hospital urology programs benchmark against, indirectly shaping demand for Eigen's semi-robotic platform.
• Siemens Healthineers (syngo.via): Siemens offers syngo.via prostate MR applications for fusion biopsy planning. As a global imaging incumbent, it overlaps with Eigen in the prostate fusion workflow but competes as part of a much broader diagnostic imaging portfolio.
• Philips (DynaCAD Prostate): Philips provides DynaCAD Prostate, an MRI visualization and analysis suite used to plan fusion-guided prostate biopsies. As a major imaging OEM with broader portfolio reach, it competes with Eigen's ProFuse CAD while bundling software with its MRI installed base.
• Hitachi (now FUJIFILM Healthcare): FUJIFILM Healthcare (successor to Hitachi's diagnostic imaging business) supplies high-end ultrasound systems and Real-Time Virtual Sonography (RVS) used in prostate fusion biopsy. It is comparable as a broad imaging incumbent whose ultrasound hardware underpins many fusion biopsy workflows.

Emerging players

• Focal Healthcare: Focal Healthcare offers the Fusion Bx and Focalyx systems for MRI-ultrasound fusion prostate biopsy. It is an emerging niche competitor with partial overlap to Eigen's Artemis and TPO products, focused on the same transrectal/transperineal fusion biopsy market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/eigenartemis1

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eigen